Reversible covalent inhibitors are governed by both formation and breakdown of the covalent complex, yet matched medicinal-chemistry modifications are often interpreted through affinity or potency alone. We performed an original quantitative reanalysis of published experimental kinetics and corresponding covalent crystal structures for four diazabicyclooctane (DBO) inhibitorsâavibactam, FPI-1465, FPI-1523, and FPI-1602âagainst CTX-M-15 and OXA-48. Relative to avibactam, all three C2-modified analogues showed lower đ2/đžđ in both enzymes, but their effects on dissociation reversed sign between targets. FPI-1465, FPI-1523, and FPI-1602 dissociated 3.86-, 3.38-, and 4.91-fold more slowly from CTX-M-15, whereas they dissociated 68.8-, 3.12-, and 2.73-fold more rapidly from OXA-48. The corresponding cross-target interactions were 265.5-, 10.5-, and 13.4-fold. Eyring transformation mapped these effects to shifts in the reverse activation barrier of +0.72 to +0.94 kcal molâ1 in CTX-M-15 versus â0.59 to â2.51 kcal molâ1 in OXA-48. Static oxyanion-hole geometry did not encode the OXA-48 ranking: mean donorâcarbonyl-oxygen distances changed by only 0.002â0.065 Ă relative to avibactam despite 2.7â68.8-fold changes in đoff. These findings identify a replicated target-dependent residence-time inversion and demonstrate that forward and reverse structureâkinetic relationships can diverge within a matched reversible-covalent series. Conformational ensembles and distributed electrostatics emerge as specific prospective mechanisms, but are not inferred as causal from the present static-structure analysis.